A Research Study to Look Into How Well Semaglutide Medicine Works at Different Doses in People With Type 2 Diabetes and Overweight

NCT05486065 on ClinicalTrials.gov · last registry update 2025-12-12

An unusually large phase 2: 245 participants, more than double the 110 typical for the stage. The sponsor logged completion for 12 October 2023. Primary outcome, as filed: Change in Glycated Haemoglobin (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 245
Started: 2022-08-08
Primary completion: 2023-10-12 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycated Haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.